Borregaard ASA (0QB7.IL)
| Previous close | 218.25 |
| Open | 221.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 219.00 - 221.50 |
| 52-week range | 130.80 - 234.50 |
| Volume | 285,725 |
| Avg. volume | 24,676 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.50 (1.10%) |
| Ex-dividend date | 15 Apr 2021 |
| 1y target est | N/A |
- Globe Newswire
Borregaard ASA: Reporting of transactions in Borregaard ASA's shares made by person discharging managerial responsibilities and closely related parties
Today, Rolf Sveinung Heggen, General Counsel, exercised 1,300 stock options at a strike price of NOK 70.95 per share, and in separate transactions purchased 1,300 shares and sold 1,200 shares. The shares are drawn from Borregaard’s holdings of treasury shares. Please, see attached notifications for persons discharging managerial responsibilities in Borregaard in accordance with Regulation EU 596/2014 (MAR) article 19. After the transactions, Rolf Sveinung Heggen and related parties own 24,410 sh
- Globe Newswire
Borregaard ASA: Reporting of transactions in Borregaard ASA's shares made by person discharging managerial responsibilities
Tove Andersen, member of the board of Borregaard ASA, has on 27 October 2021 purchased 2,000 shares in Borregaard ASA at a price of NOK 212.2273 per share. Following this transaction, Tove Andersen owns 6,000 shares in Borregaard ASA. The shares are purchased at Oslo Stock Exchange. Shareholder-elected board members shall use 20% of their gross remuneration to purchase shares in the company until they own shares equal in value to one year’s gross board remuneration. The shares shall be retained
- Globe Newswire
Borregaard ASA: EBITDA1 NOK 391 million in the 3rd quarter
Borregaard’s operating revenues reached NOK 1,429 million (NOK 1,260 million)2 in the 3rd quarter of 2021. EBITDA increased to NOK 391 million (NOK 266 million). BioSolutions’ result improved significantly. Fine Chemicals also improved, whereas BioMaterials had a result in line with last year. The net currency impact on EBITDA was slightly positive compared with the 3rd quarter of 2020. The continued impact from increased sales prices and a favourable product mix were the main reasons for the EB
